ArticleJournal of molecular histology2025
CYP2E1 overexpression in hepatocellular carcinoma modulates tumor invasion and migration via Wnt/β-catenin signaling pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Testosterone propionate maintains autophagic flux and mitochondrial integrity via regulation of the LC3B/p62/Beclin-1/mTOR axis in induced liver fibrosis.Journal of molecular histology · 2026Article
- Cytochrome P450 enzymes as modulators of oncogenic signaling via the Wnt/β-catenin signaling pathway.Archives of toxicology · 2026Review
- Untargeted metabolomics reveals3 Biotech · 2025Article
- Regulatory role of lncRNA MSTRG.11540.1 on the novel-m1192-3p/CYP2C70 axis in modulating albendazole resistance in Haemonchus contortus.BMC veterinary research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the primary cause of cancer-related mortality in the world. Cytochrome P450 2E1 (CYP2E1) plays a key role in metabolizing xenobiotics and toxic substances. The attempts to target CYP2E1 with inhibitors have yielded limited success in cancer treatment. Loss and gain-of-function experiments were performed to investigate the effects of CYP2E1 on HepG2 and Hepa 1-6 cells. Migration, invasion, intracellular reactive oxygen species (ROS) accumulation, and mitochondrial membrane potential were assessed in HepG2 cells. In vivo histopathological alterations were studied in DEN-administered rat models. Western blotting was performed to evaluate the mechanistic activation of the Wnt/β-catenin signaling pathway. In our pursuit, to elucidate the impact of CYP2E1 in carcinogenesis we revealed that in vitro, overexpression of CYP2E1 enhances the migration, invasion, increases the accumulation of intracellular ROS, and reduces the loss of mitochondrial membrane potential of HepG2 cells. In contrast, siRNA-mediated silencing of CYP2E1 produced the opposite effects. Histopathological analysis of liver sections showed pathological features such as clear cell foci, bile duct proliferation, inflammatory cell infiltration and nodule formation. In vitro and in vivo, mechanistic analysis demonstrated that CYP2E1 overexpression significantly activated the Wnt/β-catenin signaling pathway in HCC cells, as evidenced by increased protein levels of β-catenin, LEF, Cyclin D1 and survivin in immunoblot study. In vivo increased β catenin, LEF and GPC3 enhance the carcinogenicity as revealed in immunohistochemistry results. Altogether, the above findings indicates that CYP2E1 has a pivotal role in the pathogenesis and progression of HCC identifying it as a potential target for liver cancer treatment.
Indexed as
Identifiers
40632359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.